Arch Biopartners Stock Performance
| ACHFF Stock | USD 0.90 0.01 1.10% |
Arch Biopartners has a performance score of 3 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.98, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Arch Biopartners are expected to decrease slowly. On the other hand, during market turmoil, Arch Biopartners is expected to outperform it slightly. Arch Biopartners right now shows a risk of 3.16%. Please confirm Arch Biopartners semi deviation, sortino ratio, semi variance, as well as the relationship between the standard deviation and value at risk , to decide if Arch Biopartners will be following its price patterns.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Arch Biopartners are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Arch Biopartners may actually be approaching a critical reversion point that can send shares even higher in January 2026. ...more
Arch |
Arch Biopartners Relative Risk vs. Return Landscape
If you would invest 85.00 in Arch Biopartners on October 1, 2025 and sell it today you would earn a total of 5.00 from holding Arch Biopartners or generate 5.88% return on investment over 90 days. Arch Biopartners is currently producing 0.1388% returns and takes up 3.1574% volatility of returns over 90 trading days. Put another way, 28% of traded otc stocks are less volatile than Arch, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Arch Biopartners Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Arch Biopartners' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Arch Biopartners, and traders can use it to determine the average amount a Arch Biopartners' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.044
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | ACHFF | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Arch Biopartners is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Arch Biopartners by adding it to a well-diversified portfolio.
Arch Biopartners Fundamentals Growth
Arch OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Arch Biopartners, and Arch Biopartners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Arch OTC Stock performance.
| Return On Asset | -0.38 | |||
| Profit Margin | (1.46) % | |||
| Operating Margin | (1.03) % | |||
| Current Valuation | 136.63 M | |||
| Shares Outstanding | 62.4 M | |||
| Price To Earning | 237.00 X | |||
| Price To Sales | 38.19 X | |||
| EBITDA | (1.08 M) | |||
| Cash And Equivalents | 585.57 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 2.31 M | |||
| Book Value Per Share | (0.07) X | |||
| Cash Flow From Operations | (2.98 M) | |||
| Earnings Per Share | 0.01 X | |||
| Total Asset | 621.64 K | |||
About Arch Biopartners Performance
By analyzing Arch Biopartners' fundamental ratios, stakeholders can gain valuable insights into Arch Biopartners' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Arch Biopartners has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Arch Biopartners has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. In addition, it develops Borg, a peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx, which are synthetic molecules that target brain tumor initiating cells and invasive glioma cells. Arch Biopartners is traded on OTC Exchange in the United States.Things to note about Arch Biopartners performance evaluation
Checking the ongoing alerts about Arch Biopartners for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Arch Biopartners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Arch Biopartners has some characteristics of a very speculative penny stock | |
| Arch Biopartners had very high historical volatility over the last 90 days | |
| Arch Biopartners has accumulated 2.31 M in total debt. Arch Biopartners has a current ratio of 0.74, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Arch Biopartners until it has trouble settling it off, either with new capital or with free cash flow. So, Arch Biopartners' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Arch Biopartners sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Arch to invest in growth at high rates of return. When we think about Arch Biopartners' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (1.39 M) with loss before overhead, payroll, taxes, and interest of (502.88 K). | |
| Arch Biopartners has accumulated about 585.57 K in cash with (2.98 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 19.0% of the company shares are held by company insiders |
- Analyzing Arch Biopartners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Arch Biopartners' stock is overvalued or undervalued compared to its peers.
- Examining Arch Biopartners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Arch Biopartners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Arch Biopartners' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Arch Biopartners' otc stock. These opinions can provide insight into Arch Biopartners' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Arch OTC Stock analysis
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |